Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts

British Journal of Cancer

Volumn 77, Issue 3, 1998, Pages 434-439

  De Cesare, M ^a   Pratesi, G ^a   Giusti, A ^b   Polizzi, D ^a   Zunino, F ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Istituto di Anatomia Patologica Veterinaria e Patologia Aviare   (Italy)

Author keywords

Apoptosis; bcl 2; Cisplatin; Lonidamine; p53

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DRUG VEHICLE; LONIDAMINE; MEGLUMINE; PROTEIN BCL 2; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

EID: 0031972970     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.69     Document Type: Article

References (30)

1. Arcamone F, Animati, F, Berettoni M, Bigioni M, Capranico G, Casazza AM, Caserini C, Cipollone A, De Cesare M, Franciotti M, Lombardi P, Madami A, Manzini S, Monteagudo E, Polizzi D, Pratesi G, Righetti SC, Salvatore C, Supino R and Zunino F (1997) A doxorubicin disaccharide analog: apoptosis-reluted improvement of efficacy in vivo. J Natl Cancer Inst 89: 1217-1223
2. Calabresi F (1994) Drug resistance: lonidamine. In Principles & Practice of Oncology, DeVita VC. Hellman S and Rosenberg SA. (eds), pp. 1-15. Lippincott: Philadelphia
3. Caserini C, Pratesi G, Tortoreto M, Bedogne' B, Carenini N, Supino R, Perego P, Righetti SC and Zunino F (1997) Apoptosis as determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinieal in vitro/in vivo studies. Clin Cancer Res 3: 955-961
4. Chitnis M and Adwankar M (1986) Potentiation of adriamycin cytotoxicity in P388 murine leukemia sensitive and resistant to adriamycin by use of lonidamine and hyperthermia. Tumori 72: 469-475
5. Cividali A, Gentile FP, Alonzi A, Benassi M, Mauro F and Floridi A (1992) In vivo control of tumor growth by lonidamine and radiation: influence of the timing and sequence of drug administration and irradiation treatment. Int J Oncol 1: 561-565
6. Del Bufalo D, Biroccio A, Soddu S, Laudonio N, D'Angelo C, Sacchi A and Zupi G (1996) Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. J Clin Invest 98: 1165-1173
7. Floridi A, Paggi MG, D'Atri S, De Martino C, Marcante ML, Silvestrini B and Caputo A (1981) Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res 41: 4661-4666.
8. Gavrieli Y, Sherman Y and Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501
9. Geran RI, Greenberg NH, MacDonald MM, Schumacher AM and Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 3: 1-88
10. Hahn GM, Van Kersen I and Silvestrini B (1984) Inhibition of the recovery from potentially lethal damage by lonidamine. Br J Cancer 50: 657-660
11. Haldar S, Jena N and Croce CM (1995) Inactivation of bcl-2 by phosphorylation. Proc. Natl Acad Sci USA 92: 4507-4511
12. Haldar S, Basil A and Croce CM (1997) BCL2 is the guardian of microtubule integrity. Cancer Res 57: 229-233
13. Hume DA and Weidemann MJ (1979) Role and regulation of glucose metabolism in proliferating cells. J Natl Cancer Inst 62: 3-8
14. Kerr JFR, Winterford CM and Harmon BV (1994) Apoptosis. Its significance in cancer and cancer therapy. Cancer 73: 2013-2026
15. Kroemer G (1997) The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med 3: 614-620
16. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685
17. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC and Zunino F (1946) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556-562
18. Pratesi G, Dal Bo L, Paolicchi A, Tonarelli P, Tongiani R and Zunino F (1995) The role of the glutathione-dependent system in tumor sensitivity to cisplatin: a study of human tumor xenografts. Ann Oncol 6: 283-289
19. Pratesi G, De Cesare M and Zunino F (1996) Efficacy of lonidamine combined with different DNA-damaging agents in the treatment of the MX-1 tumor xenograft. Cancer Chemother Pharmacol 38: 123-128
20. Raaphorst GP, Feeley MM, Heller DP, Danjoux CE, Martin L, Maroun JA and De Sanctis AJ (1990) Lonidamine can enhance the cytotoxic effect of cisplatin in human tumour cells and rodent cells. Anticancer Res 10: 923-928
21. Reed JC (1994) Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6
22. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G and Zunino F (1996) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56: 689-693
23. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M and Dmitrovsky E (1995) Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55: 5038-5042
24. Sarti P, Antonini G, Arancia G, Blanck TJ, Citro G, Meloni A, Molinari A and Malatesta F (1994) Lonidamine-mediated respiratory changes in rat heart myocytes: a re-examination of the functional response of mitochondrial cytochrome c oxidase. Biochem Pharmacol 47, 2221-2225
25. Silvestrini B (1991) Lonidamine: an overview. Semin Oncol 18: 2-6
26. Teicher BA, Herman TS, Holden SA, Epelbaum R, Liu S and Frei E III (1991) Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. Cancer Res 51, 780-784
27. Zaffaroni N, Bearzatto A, Gornati D and Silvestrini R (1994) Effect of lonidamine on the cytotoxic activity of cisplatin, mitomycin C and BCNU in human ovarian and colon carcinoma cells. Int J Oncol 4: 773-778
28. Zupi G, Greco C, Laudonio N, Benassi M, Silvestrini B and Caputo A (1986) In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin. Anticancer Res 6: 1245-1250
29. Workman P, Balmain A, Hickman JA, McNally NJ, Mitchison NA, Pierrepoint CG, Raymond R, Rowlatt C, Stephens TC and Wallace J (1988) UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 58: 109-113
30. Wu GS and El-Deiry WS (1996) Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or Bcl-2. Clin Cancer Res 2: 623-633